<DOC>
	<DOCNO>NCT00096967</DOCNO>
	<brief_summary>This multicenter , open-label extension study . Subjects receive rhuMAb VEGF therapy Study AVF2107g , AVF2119g , AVF2192g complete parent study eligible inclusion trial . Subjects receive placebo Study AVF2107g AVF2192g also eligible .</brief_summary>
	<brief_title>A Study Evaluate Avastin Patients Treated Previous Genentech-Sponsored Cancer Study</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Written inform consent Previous participation completion one following Genentechsponsored rhuMAb VEGF Phase II Phase III cancer study : AVF2107g , AVF2119g , AVF2192g Use effective mean contraception men woman childbearing potential For subject receive placebo parent study , current antitumor therapy exceed thirdline treatment disease progression Compromised renal hepatic function , define parent protocol EGOG status 3 great Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study Genentechsponsored rhuMAb VEGF cancer study ANC &lt; 1500/uL Platelet count &lt; 75,000/uL International normalized ration ( INR ) &gt; =1.5 ( except subject give approval receive fulldose warfarin plus rhuMAb VEGF ) Total bilirubin &gt; 1.6 mg/dL patient receive irinotecan , others total bilirubin &gt; 2.0 mg/dL AST ALT &gt; 5 time upper limit normal subject document liver metastasis ; &gt; 2.5 time upper limit normal subject without evidence liver metastasis Serum creatinine &gt; 2.0 mg/dL Hemoglobin &lt; 9 gm/dL ( may transfuse receive epoetin alfa [ e.g. , Epogen ] maintain exceed level ) Inability comply study and/or followup procedure History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render subject high risk treatment complication Any unresolved irreversible rhuMAb VEGFrelated ongoing serious adverse event occur parent study Clinically significant cardiovascular disease ( e.g. , uncontrolled hypertension [ blood pressure &gt; 160/110 mmHg medication ] , previous myocardial infarction , unstable angina ) , New York Heart Association ( NYHA ) Grade II great congestive heart failure , serious cardiac dysrhythmia require medication , peripheral vascular disease ( Grade II great ) History evidence upon physical examination CNS disease ( e.g. , primary brain tumor , seizures control standard medical therapy , brain metastasis , history stroke ) Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 0 , anticipation need major surgical procedure course study Fine needle aspiration core biopsy within 7 day prior Day 0 Chronic , daily treatment aspirin ( &gt; 325 mg/day ) nonsteroidal anti inflammatory medication ( kind know inhibit platelet function dos use treat chronic inflammatory disease ) Pregnancy ( positive pregnancy test ) lactation Proteinuria baseline clinically significant impairment renal function Serious , nonhealing wound , ulcer , bone fracture Evidence bleed diathesis coagulopathy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>Metastatic colorectal cancer</keyword>
</DOC>